Aisling Capital Management LP
CIK 0001766721 · NEW YORK, NY · Quarter end: 2026-06-30 · Filed on: 2026-08-13 · Open the SEC source ↗
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$471.6M
2026 Q2
Positions
14
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
99.0%
Est. Net Flow (Q)
—
2026 Q2
Top Holdings
BBIO
BRIDGEBIO PHARMA INC
72.5%
GLUE
MONTE ROSA THERAPEUTICS INC
8.0%
SNDX
SYNDAX PHARMACEUTICALS INC
6.1%
CMPS
COMPASS PATHWAYS PLC
4.3%
BCAX
BICARA THERAPEUTICS INC
3.6%
BBOT
BRIDGEBIO ONCOLOGY THERAPEUT
1.6%
SRRK
SCHOLAR ROCK HLDG CORP
0.9%
URGN
UROGEN PHARMA LTD
0.8%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.